Survival Improving in Metastatic Bladder Cancer Cases
Trend may reflect increasing use of systemic immunotherapies as first-line treatments, according to investigators.
Diagnosis & Disease Information
Performance Scores Predict Immune Checkpoint Inhibitor-Related Adverse Events
An analysis of data from patients with cancer treated with immune checkpoint inhibitors sought to determine predictors of immune-related adverse effects in these patients.
Neoadjuvant Pembrolizumab Shows Promise for Cisplatin-Ineligible MIBC
There is an unmet need for systemic treatment options in patients with muscle-invasive bladder cancer who are ineligible for cisplatin-based neoadjuvant chemotherapy, according to investigators.
Presence of rhAbs Associated With Immune Checkpoint Inhibitor-Related Adverse Events
A retrospective review of patients with cancer treated with ICI therapy sought to determine an association between rheumatic autoantibodies in patients without preexisting autoimmune disease and irAEs.
Daratumumab Extends OS in Relapsed/Refractory Multiple Myeloma
Adding daratumumab to lenalidomide and dexamethasone extends overall survival in relapsed/refractory multiple myeloma, according to final results from the POLLUX trial.
ICD Codes Unreliable for Identifying Cardiovascular Events in ICI-Treated Patients
Researchers sought to determine CV event occurrence in patients treated with immune checkpoint inhibitors and assess the accuracy of diagnosis by ICD code compared with adjudication using established definitions.
Cytoreductive Nephrectomy Added to ICI Therapy Ups Survival in mRCC
Use of cytoreductive nephrectomy with an immune checkpoint inhibitor reduced death risk by 67%.
Adaptive Nivolumab Plus Ipilimumab Improves Outcomes in mRCC
Final results from the TITAN-RCC trial demonstrate improvements in objective response rates compared with nivolumab monotherapy.
Treatment Sequence Studied for Advanced BRAF-Mutant Melanoma
Two-year overall survival higher for those initiating treatment with combo nivolumab/ipilimumab versus dual BRAF/MEK inhibition.
Analysis of Sacituzumab Govitecan Shows Manageable Safety Profile in mTNBC
Researchers report on the safety data from the phase 3 ASCENT trial of sacituzumab govitecan in the treatment of metastatic triple-negative breast cancer.
- Loading...
Loading...
Next post in Breast Cancer
Loading... 
Loading...